OBJECTIVES: To determine if there is an association of hemoglobin level before or during concurrent cisplatin and radiotherapy (RT) with disease outcome in women with locally advanced cervical cancer, and to assess if the association is particularly significant at a specific interval or time during treatment. METHODS: A retrospective review of 494 patients treated on two consecutive prospective Gynecologic Oncology Group (GOG) trials was conducted. Demographic data, pathologic information, treatment-related factors, and hemoglobin values at baseline and during each week of therapy were collected. Cox proportional hazards model was performed to evaluate the impact of hemoglobin level on progression-free survival (PFS). RESULTS: Of the combined patients, 278 (56%) and 216 (44%) were diagnosed with Stage II and Stage III/IV disease, respectively. Controlling for age, race, performance status, disease stage, tumor size, cell type, and duration of radiotherapy, mean hemoglobin values during treatment were predictive of disease progression (P < 0.0001). The pretreatment level was not significant when hemoglobin levels during treatment were included in the multivariate analysis. When the 6-week treatment course was divided into 2-week periods (early, middle, and late), analysis revealed hemoglobin values during the late period were the most predictive of disease progression (P = 0.0289). CONCLUSIONS:Hemoglobin levels during combined radiotherapy and cisplatin were independent predictors of treatment outcome in advanced cervical carcinoma. The pretreatment level was not a significant predictor of outcome when hemoglobin levels during treatment were included in the multivariate regression model. Levels in the last part of treatment were the most predictive of disease recurrence and survival.
RCT Entities:
OBJECTIVES: To determine if there is an association of hemoglobin level before or during concurrent cisplatin and radiotherapy (RT) with disease outcome in women with locally advanced cervical cancer, and to assess if the association is particularly significant at a specific interval or time during treatment. METHODS: A retrospective review of 494 patients treated on two consecutive prospective Gynecologic Oncology Group (GOG) trials was conducted. Demographic data, pathologic information, treatment-related factors, and hemoglobin values at baseline and during each week of therapy were collected. Cox proportional hazards model was performed to evaluate the impact of hemoglobin level on progression-free survival (PFS). RESULTS: Of the combined patients, 278 (56%) and 216 (44%) were diagnosed with Stage II and Stage III/IV disease, respectively. Controlling for age, race, performance status, disease stage, tumor size, cell type, and duration of radiotherapy, mean hemoglobin values during treatment were predictive of disease progression (P < 0.0001). The pretreatment level was not significant when hemoglobin levels during treatment were included in the multivariate analysis. When the 6-week treatment course was divided into 2-week periods (early, middle, and late), analysis revealed hemoglobin values during the late period were the most predictive of disease progression (P = 0.0289). CONCLUSIONS: Hemoglobin levels during combined radiotherapy and cisplatin were independent predictors of treatment outcome in advanced cervical carcinoma. The pretreatment level was not a significant predictor of outcome when hemoglobin levels during treatment were included in the multivariate regression model. Levels in the last part of treatment were the most predictive of disease recurrence and survival.
Authors: Gillian Thomas; Shamshad Ali; Frank J P Hoebers; Kathleen M Darcy; William H Rodgers; Malti Patel; Ovardia Abulafia; Joseph A Lucci; Adrian C Begg Journal: Gynecol Oncol Date: 2007-11-26 Impact factor: 5.482
Authors: Sujana Movva; Anne-Michelle Noone; Mousumi Banerjee; Divya A Patel; Kendra Schwartz; Cecilia L Yee; Michael S Simon Journal: Cancer Date: 2008-03-15 Impact factor: 6.860
Authors: Hedwig P van de Nieuwenhof; Joanne A de Hullu; Johannes H A M Kaanders; Johan Bulten; Leon F A G Massuger; Léon C L T van Kempen Journal: Virchows Arch Date: 2010-10-02 Impact factor: 4.064
Authors: M Tampellini; A Saini; I Alabiso; R Bitossi; M P Brizzi; C M Sculli; A Berruti; G Gorzegno; A Magnino; E Sperti; S Miraglia; L Forti; O Alabiso; M Aglietta; A Harris; L Dogliotti Journal: Br J Cancer Date: 2006-06-13 Impact factor: 7.640
Authors: Rūta Grigiene; Konstantinas P Valuckas; Eduardas Aleknavicius; Juozas Kurtinaitis; Simona R Letautiene Journal: BMC Cancer Date: 2007-12-22 Impact factor: 4.430